Picture of offices in the City of London

Open Access research that is better understanding work in the global economy...

Strathprints makes available scholarly Open Access content by researchers in the Department of Work, Employment & Organisation based within Strathclyde Business School.

Better understanding the nature of work and labour within the globalised political economy is a focus of the 'Work, Labour & Globalisation Research Group'. This involves researching the effects of new forms of labour, its transnational character and the gendered aspects of contemporary migration. A Scottish perspective is provided by the Scottish Centre for Employment Research (SCER). But the research specialisms of the Department of Work, Employment & Organisation go beyond this to also include front-line service work, leadership, the implications of new technologies at work, regulation of employment relations and workplace innovation.

Explore the Open Access research of the Department of Work, Employment & Organisation. Or explore all of Strathclyde's Open Access research...

The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels

Barbour, Mark and Wood, Rachel and Hridi, Shehla U and Wilson, Chelsey and McKay, Grant and Bushell, Trevor J and Jiang, Hui-Rong (2018) The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels. Journal of Neuroimmunology. pp. 1-33. ISSN 0165-5728

[img] Text (Barbour-etal-JN2018-The-therapeutic-effect-of-anti-CD52-treatment-in-murine)
Barbour_etal_JN2018_The_therapeutic_effect_of_anti_CD52_treatment_in_murine.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 24 February 2019.
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (621kB) | Request a copy from the Strathclyde author

Abstract

Experimental autoimmune encephalomyelitis (EAE) mice were administered with murine anti-CD52 antibody to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and central nervous system (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral T and B lymphocyte depletion and reduced production of various cytokines including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33+ cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2+ cells in the spinal cord of treated EAE mice was downregulated due to decreased inflammation and immune cell infiltration in the CNS. These results suggest that treatment with anti-CD52 antibody differentially alters expression of IL-33 and ST2, both systemically and within the CNS, which may indicateIL-33/ST2 axis is involved in the action of the antibody in inhibiting EAE.